Co-dergocrine (Hydergine) in the treatment of tardive dyskinesia

1982 ◽  
Vol 12 (2) ◽  
pp. 427-429 ◽  
Author(s):  
Sudhir C. Rastogi ◽  
Anthony J. Blowers ◽  
Alan C. Gibson
Keyword(s):  
Tardive Dyskinesia ◽  
Psychiatric Patients ◽  
Statistical Significance ◽  
Dosage Level ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Active Medication ◽  
Younger Patient ◽  
Chronic Psychiatric Patients

SynopsisIn a double-blind, placebo-controlled study with co-dergocrine in the treatment of tardive dyskinesia in a group of elderly chronic psychiatric patients the reduction of dyskinetic scores in the group receiving active medication was slightly greater than that in the placebo group; however, this difference did not reach a level of statistical significance. It is suggested that further work could be undertaken with a longer period of treatment, and at a higher dosage level of co-dergocrine, in a younger patient sample.

The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study

1988 ◽  
Vol 12 (4) ◽  
pp. 533-539 ◽  
Author(s):  
Matsunaga Tetsuo ◽  
Ohyama Shigeru ◽  
Takehara Shigeharu ◽  
Kabashima Keikichi ◽  
Moriyama Shigeru ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study

2015 ◽  
Vol 30 (12) ◽  
pp. 1681-1687 ◽  
Author(s):  
Christopher F. O'Brien ◽  
Roland Jimenez ◽  
Robert A. Hauser ◽  
Stewart A. Factor ◽  
Joshua Burke ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Monoamine Transport ◽  
Transport Inhibitor

Effect of Sodium Valproate on Tardive Dyskinesia

1976 ◽  
Vol 129 (2) ◽  
pp. 114-119 ◽  
Author(s):  
M. Linnoila ◽  
M. Viukari ◽  
O. Hietala
Keyword(s):  
Tardive Dyskinesia ◽  
Sodium Valproate ◽  
Psychiatric Symptoms ◽  
Psychiatric Patients ◽  
The Elderly ◽  
Elderly Subjects ◽  
Gamma Aminobutyric Acid ◽  
Double Blind ◽  
Psychiatric State ◽  
Chronic Psychiatric Patients

SummaryThe effect of sodium valproate, a drug which has been demonstrated to increase gamma-aminobutyric acid levels in the CNS, on tardive dyskinesia and psychiatric symptoms was investigated in a double-blind cross-over study on 32 chronic psychiatric patients. The oro-facial dyskinesias were totally or significantly relieved in 17 cases. During the active treatment period the involuntary movements of the extremities and dystonic spasms were also significantly relieved in 7 out of 9 patients. In two patients, however, the extrapyramidal symptoms became slightly worse. A significant improvement was noted in the psychiatric symptoms of 14 out of 32 patients during sodium valproate administration. The psychiatric state of 4 out of 32 patients deteriorated. There was no correlation between the serum concentration of sodium valproate and its effect on the dyskinesia or on the psychiatric symptoms. Some of the elderly subjects showed a slight accumulation of the drug.

Treatment of tardive dyskinesia with ceruletide: A double-blind, placebo-controlled study

1992 ◽  
Vol 43 (2) ◽  
pp. 129-136 ◽  
Author(s):  
Takuya Kojima ◽  
Toshio Yamauchi ◽  
Matsue Miyasaka ◽  
Yoshifumi Koshino ◽  
Yoshibumi Nakane ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Safety and Efficacy of Probiotic Supplementation in Reducing the Incidence of Infections and Modulating Inflammation in the Elderly with Feeding Tubes: A Pilot, Double-Blind, Placebo-Controlled Study, “IntegPRO”

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 391
Author(s):  
Paolo Orlandoni ◽  
Nikolina Jukic Peladic ◽  
Angela Amoruso ◽  
Marco Pane ◽  
Mirko Di Rosa ◽  
...  
Keyword(s):  
Nutritional Status ◽  
Statistical Significance ◽  
Intervention Group ◽  
Clinical Manifestations ◽  
Bowel Function ◽  
The Elderly ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Reactive Protein

A double-blind, placebo-controlled study was performed in a sample of geriatric patients treated with home enteral nutrition (HEN) to analyze the efficacy of a probiotic supplement Proxian®, which contains Lactiplantibacillus plantarum LP01 (LMG P-21021), Lentilactobacillus buchneri Lb26 (DSM 16341), Bifidobacterium animalis subsp. lactis BS01 (LMG P-21384), and is enriched with zinc (Zn) and selenium (Se), in reducing the incidence of infections and modulating inflammation. Thirty-two subjects were enrolled (mean age 79.7 ± 10.3 years), 16 in the intervention group, 16 controls. They received Proxian® or placebo for 60 days. Patients were assessed at baseline (t0) and 60 (t1) and 90 (t2) days after the beginning. Infections were detected by information regarding their clinical manifestations and the incidence of antibiotic therapy. Levels of C-reactive protein (CRP) were measured to study inflammation. Information on bowel function, nutritional status and testimonials regarding the feasibility of administration of the product were collected. Differences between the two groups in number of infections (25% intervention group vs. 44% controls), antibiotic therapies (12% vs. 37%) and modulation of CRP levels (median CRP moved from 0.95 mg/L (t0), to 0.6 (t1) and 0.7 (t2) in intervention group vs. 0.7 mg/L, 0.5 and 0.7 in controls) did not reach statistical significance. No significant changes in bowel function and nutritional status were found. Caregivers’ adherence was 100%. Results of this “IntegPRO” study showed that Proxian® is potentially safe, easy to administer and promising for further studies but it appears not to change the incidence of infections or modulate inflammation in elderly treated with HEN. The utility of Proxian® in reducing the incidence of infections and modulating inflammation in these subjects needs to be investigated by a larger multi-center clinical trial, and by using additional analyses on inflammatory markers and markers of infections.

Oxypertine in Tardive Dyskinesia: An 8-week Controlled Study

1984 ◽  
Vol 144 (1) ◽  
pp. 48-52 ◽  
Author(s):  
S. D. Soni ◽  
H. L. Freeman ◽  
E. M. Hussein
Keyword(s):  
Tardive Dyskinesia ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

SummaryIn a double-blind placebo controlled trial of oxypertine in the treatment of tardive dyskinesia, 33 patients with chronic schizophrenia received either oxypertine or placebo. At the end of eight weeks, the results showed that oxypertine was superior to placebo at a statistically significant level.

Sign in / Sign up

Export Citation Format

Share Document